We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Technology Developed to Capture Tumor Cells

By LabMedica International staff writers
Posted on 28 May 2019
The roles and clinical values circulating tumor cells (CTCs) are under intensive investigation, yet most studies are limited by technical challenges in the comprehensive enrichment of intact and viable CTCs with minimal white blood cell (WBC) contamination.

CTCs break away from cancerous tumors and flow through the bloodstream, potentially leading to new metastatic tumors. The isolation of CTCs from the blood provides a minimally invasive alternative for basic understanding, diagnosis and prognosis of metastatic cancer.

Image: The integrated ferrohydrodynamic cell separation (iFCS) device that enriches circulating tumor cells (CTCs) in a tumor antigen-independent and cell size variation-inclusive manner (Photo courtesy of the University of Georgia).
Image: The integrated ferrohydrodynamic cell separation (iFCS) device that enriches circulating tumor cells (CTCs) in a tumor antigen-independent and cell size variation-inclusive manner (Photo courtesy of the University of Georgia).

Chemists at the University of Georgia (Athens, GA, USA) and their collaborators developed a device, about the size of a USB drive, works by funneling blood through channels smaller in diameter than a human hair. To prepare blood for analysis, the team adds micron-sized magnetic beads to the samples. The white blood cells in the sample attach themselves to these beads. As blood flows through the device, magnets on the top and bottom of the chip draw the white blood cells and their magnetic beads down a specific channel while the circulating tumor cells continue into another channel.

The novel method based on contrast of cell magnetization in biocompatible ferrofluids (a colloidal magnetic nanoparticle suspension), termed as integrated ferrohydrodynamic cell separation (iFCS), that enriches CTCs in a tumor antigen-independent and cell size variation-inclusive manner, achieves a high throughput (12 mL per hour), with a high recovery rate (99.08% at down to ∼10 cells per mL spike ratio), and low WBC contamination (533 cells for every one milliliter blood processed) and is biocompatible.

Melissa B. Davis, PhD, an assistant professor and co-author of the study, said, “Physicians can only treat what they can detect. We often can't detect certain subtypes of CTCs, but with the iFCS device we will capture all the subtypes of CTCs and even determine which subtypes are the most informative concerning relapse and disease progression.” The study was published on April 27, 2019, in the journal Lab on a Chip.

Related Links:
University of Georgia


Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA
New
Human Insulin CLIA
Human Insulin CLIA Kit

Latest Technology News

Optical Biosensor Rapidly Detects Monkeypox Virus at Point of Care

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

New Noninvasive Methods Detect Lead Exposure Faster, Easier and More Accurately at POC